Products
Invikafusp Biosimilar Fusion Protein (TRBV6 / TRBV10) for Research
Cat No.: GMP-Bios-INN-1240
Anti-TRBV6&TRBV10 therapeutic antibody (Pre-made Invikafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Invikafusp (development code STAR 0602) is a fusion protein. It is developed by Marengo Therapeutics for Solid tumours in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1240-1mg | 1mg | 3090 |
| GMP-Bios-INN-1240-10mg | 10mg | |
| GMP-Bios-INN-1240-100mg | 100mg | |
| GMP-Bios-INN-1240-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Invikafusp biosimilar, Fusion Protein: Recombinant therapeutic protein targeting TRBV6&TRBV10 |
| INN Name | Invikafusp |
| Target | TRBV6&TRBV10 |
| Format | Fusion Protein |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 8tfn:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Marengo Therapeutics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
